benzofurans and pridopidine

benzofurans has been researched along with pridopidine* in 1 studies

Other Studies

1 other study(ies) available for benzofurans and pridopidine

ArticleYear
Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [
    European journal of nuclear medicine and molecular imaging, 2021, Volume: 48, Issue:4

    Using [. S1R occupancy as function of pridopidine dose (or plasma concentration) in HVs could be described by a three-parameter Hill equation with a Hill coefficient larger than one. A high degree of S1R occupancy (87% to 91%) was found throughout the brain at pridopidine doses ranging from 22.5 to 90 mg. S1R occupancy was 43% at 1 mg pridopidine. In contrast, at 90 mg pridopidine, the D2/D3R occupancy was only minimal (~ 3%).. Our PET findings indicate that at clinically relevant single dose of 90 mg, pridopidine acts as a selective S1R ligand showing near to complete S1R occupancy with negligible occupancy of the D2/D3R. The dose S1R occupancy relationship suggests cooperative binding of pridopidine to the S1R. Our findings provide significant clarification about pridopidine's mechanism of action and support further use of the 45-mg twice-daily dose to achieve full and selective targeting of the S1R in future clinical trials of neurodegenerative disorders. Clinical Trials.gov Identifier: NCT03019289 January 12, 2017; EUDRA-CT-Nr. 2016-001757-41.

    Topics: Benzamides; Benzofurans; Brain; Dopamine; Healthy Volunteers; Humans; Huntington Disease; Male; Piperidines; Positron-Emission Tomography; Receptors, Dopamine D2; Receptors, Dopamine D3

2021